Thomas Wölfel

8.2k citations

70 papers · 6.4k indexed · 3 hit papers · h-index 32

Impact in

Immunology top 0.2%
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
Oncology top 0.5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in ⓘ

Immunology 60
- Immunotherapy and Immune Responses 53
- T-cell and B-cell Immunology 32
- Immune Cell Function and Interaction 21
Oncology 21
- CAR-T cell therapy research 15
- Cancer Immunotherapy and Biomarkers 6

Co-authors: Thierry Boon (13 shared papers)Aline Van Pel (12 shared papers)Etienne De Plaen (7 shared papers)Vincent Brichard (9 shared papers)Catherine Wölfel (14 shared papers)Karl‐Hermann Meyer zum Büschenfelde (9 shared papers)Jörg Schneider (6 shared papers)Pierre G. Coulie (3 shared papers)
Journals: International Journal of Cancer (8 papers)Journal of Immunological Methods (6 papers)The Journal of Experimental Medicine (4 papers)Proceedings of the National Academy of Sciences (4 papers)The Journal of Immunology (3 papers)
Partner nations: Germany Belgium United States

In The Last Decade

Thomas Wölfel

68 papers receiving 6.3k citations

Hit Papers

align trajectories log scale

A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma 1995 · 900 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1995 Science
1994 The Journal of Experimental Medicine
1993 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Thomas Wölfel

Since Specialization

Citations

This map shows the geographic impact of Thomas Wölfel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Wölfel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Wölfel more than expected).

Fields of papers citing papers by Thomas Wölfel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Wölfel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Wölfel. The network helps show where Thomas Wölfel may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Wölfel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Wölfel Line = papers co-authored together Thomas Wölfel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 70 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma Science ·Thomas Wölfel, Martina Hauer, Jörg Schneider, Manuel Serrano, Catherine Wölfel, Eva Klehmann-Hieb, Etienne De Plaen, Thomas Hankeln, Karl‐Hermann Meyer zum Büschenfelde, David Beach Hit paper breakdown →	1995	900
2	The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of Experimental Medicine ·Vincent Brichard, Aline Van Pel, Thomas Wölfel, Catherine Wölfel, Etienne De Plaen, Bernard Lethé, Pierre G. Coulie, Thierry Boon Hit paper breakdown →	1993	785
3	A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of Experimental Medicine ·Pierre G. Coulie, Vincent Brichard, Aline Van Pel, Thomas Wölfel, J. Schneider, Catia Traversari, S Mattei, Etienne De Plaen, Christophe Lurquin, Jean‐Pierre Szikora, Jean‐Christophe Renauld, Thierry Boon Hit paper breakdown →	1994	767
4	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation Nature ·Jennifer Landsberg, Judith Kohlmeyer, Marcel Renn, Tobias Bald, Meri Rogava, Mira Cron, Martina Fatho, Volker Lennerz, Thomas Wölfel, Michael Hölzel, Thomas Tüting	2012	448
5	The response of autologous T cells to a human melanoma is dominated by mutated neoantigens Proceedings of the National Academy of Sciences ·Volker Lennerz, Martina Fatho, Chiara Gentilini, Roy A. Frye, Alexander Lifke, Dorothea Ferel, Catherine Wölfel, Christoph Huber, Thomas Wölfel	2005	348
6	An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. The Journal of Experimental Medicine ·Jonathan Skipper, Ronald C. Hendrickson, Pamela H. Gulden, Vincent Brichard, Aline Van Pel, Y Chen, Jeffrey Shabanowitz, Thomas Wölfel, Craig L. Slingluff, Thierry Boon, Donald F. Hunt, Víctor H. Engelhard	1996	346
7	Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes European Journal of Immunology ·Thomas Wölfel, Aline Van Pel, Vincent Brichard, Jörg Schneider, Barbara Seliger, Karl‐Hermann Meyer zum Büschenfelde, Thierry Boon	1994	345
8	Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proceedings of the National Academy of Sciences ·Etienne De Plaen, Christophe Lurquin, Aline Van Pel, Bernard Mariamé, Jean‐Pierre Szikora, Thomas Wölfel, Catherine Sibille, Patrick Chomez, Thierry Boon	1988	231
9	Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. The Journal of Experimental Medicine ·Thomas Wölfel, E. Klehmann, Claude P. Muller, K.-H. Schütt, K. H. Meyer zum Büschenfelde, Alexander Knuth	1989	191
10	Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proceedings of the National Academy of Sciences ·Alexander Knuth, Thomas Wölfel, E. Klehmann, Thierry Boon, K. H. Meyer zum Büschenfelde	1989	157
11	Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens Journal of Immunological Methods ·Wolfgang Herr, Jörg Schneider, Ansgar W. Lohse, Karl‐Hermann Meyer zum Büschenfelde, Thomas Wölfel	1996	155
12	Cytolytic T lymphocyte recognition of the immunodominant HLA-A0201-restricted Melan-A/MART-1 antigenic peptide in melanoma The Journal of Immunology* ·Pedro Romero, Nadine Gervois, J. Schneider, Patricia Escobar, Danila Valmori, Christophe Pannetier, Alexander Steinle, Thomas Wölfel, D. Liénard, Vincent Brichard, Aline Van Pel, Francine Jotereau, J.-C. Cerottini	1997	138
13	The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens Journal of Immunological Methods ·Wolfgang Herr, Bruno Linn, Nicole Leister, E Wandel, Karl‐Hermann Meyer zum Büschenfelde, Thomas Wölfel	1997	120
14	A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes European Journal of Immunology ·Vincent Brichard, Jean Herman, Aline Van Pel, Claude Wildmann, Béatrice Gaugler, Thomas Wölfel, Thierry Boon, Bernard Lethé	1996	108
15	The use of HLA-A0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays Journal of Immunological Methods* ·Cedrik M. Britten, Ralf G. Meyer, Tanja Kreer, Ingo Drexler, Thomas Wölfel, Wolfgang Herr	2002	105
16	Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL) International Journal of Cancer ·Thomas Wölfel, M. Hauer, E. Klehmann, Vincent Brichard, Birgit Ackermann, Alexander Knuth, Thierry Boon, K. H. Meyer zum Büschenfelde	1993	90
17	Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proceedings of the National Academy of Sciences ·Marialuisa Sensi, Catia Traversari, Marina Radrizzani, Stefania Salvi, Cristina Maccalli, Roberta Mortarini, Licia Rivoltini, Cinthia Farina, Gabriella Nicolini, Thomas Wölfel	1995	86
18	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency Cancer Research ·Fang Zhao, Antje Sucker, Susanne Horn, Christina Heeke, Nicola Bielefeld, Barbara Schrörs, Anne Bicker, Monika Lindemann, Alexander Roesch, Gustav Gaudernack, Mathias Stiller, Jürgen C. Becker, Volker Lennerz, Thomas Wölfel, Dirk Schadendorf, Klaus Griewank, Annette Paschen	2016	57
19	Quantitative and functional analysis of core‐specific T‐helper cell and CTL activities in acute and chronic hepatitis B Liver International ·H Löhr, Sandra Krug, Wolfgang Herr, Sandra Weyer, JF Schlaak, Thomas Wölfel, Guido Gerken, Karl‐Hermann Meyer zum Büschenfelde	1998	56
20	Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2 Cancer Immunology Immunotherapy ·Julia Steitz, Cedrik M. Britten, Thomas Wölfel, Thomas Tüting	2005	54

About Thomas Wölfel

Thomas Wölfel is a scholar working on Immunology, Oncology, Virology, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 70 papers that have together received 6.4k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (53 papers), T-cell and B-cell Immunology (32 papers), Immune Cell Function and Interaction (21 papers), vaccines and immunoinformatics approaches (18 papers), CAR-T cell therapy research (15 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), RNA Interference and Gene Delivery (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). The work is most often cited by research in Immunology (5.1k citations), Oncology (2.8k citations), Molecular Biology (2.8k citations), Radiology, Nuclear Medicine and Imaging (612 citations) and Biotechnology (185 citations). Thomas Wölfel has collaborated with scholars based in Germany, Belgium and United States. Frequent co-authors include Thierry Boon, Aline Van Pel, Etienne De Plaen, Vincent Brichard, Catherine Wölfel, Karl‐Hermann Meyer zum Büschenfelde, Jörg Schneider, Pierre G. Coulie, Bernard Lethé and Volker Lennerz. Their work appears in journals such as International Journal of Cancer, Journal of Immunological Methods, The Journal of Experimental Medicine, Proceedings of the National Academy of Sciences and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact